Piper Jaffray upgrades Biogen Idec (Nasdaq: BIIB) from Sell to Neutral with a $65 price target.

The firm said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE